États-Unis - anglais - NLM (National Library of Medicine)

proficient rx lp - sotalol hydrochloride (unii: hec37c70xx) (sotalol - unii:a6d97u294i) - sotalol hydrochloride tablets are indicated for the treatment of life-threatening, documented ventricular arrhythmias, such as sustained ventricular tachycardia (vt). limitation of use: sotalol hydrochloride tablets may not enhance survival in patients with ventricular arrhythmias. because of the proarrhythmic effects of sotalol hydrochloride tablets, including a 1.5 to 2% rate of torsade de pointes (tdp) or new ventricular tachycardia/fibrillation (vt/vf) in patients with either non-sustained ventricular tachycardia (nsvt) or supraventricular arrhythmias (svt), its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. avoid treatment of patients with asymptomatic ventricular premature contractions [see warnings and precautions (5.2)]. sotalol hydrochloride tablets are indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of afib/afl) in patients with symptomatic afib/afl who are currently in sinus rhythm. limitation of us

États-Unis - anglais - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - sotalol hydrochloride (unii: hec37c70xx) (sotalol - unii:a6d97u294i) - sotalol hydrochloride tablets, usp are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. because of the proarrhythmic effects of sotalol hydrochloride tablets, usp (see warnings ), including a 1.5 to 2% rate of torsade de pointes or new vt/vf in patients with either nsvt or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of sotalol hydrochloride treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. the response to treatment should then be evaluated by a suitable method (e.g., pes or holter monitoring) prior to continuing the patient on chronic therapy. vario

Belgique - anglais - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - sotalol hydrochloride 160 mg - tablet - 160 mg - sotalol hydrochloride 160 mg - sotalol

Belgique - anglais - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - sotalol hydrochloride 160 mg - tablet - 160 mg - sotalol hydrochloride 160 mg - sotalol

Belgique - anglais - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - sotalol hydrochloride 80 mg - tablet - 80 mg - sotalol hydrochloride 80 mg - sotalol

États-Unis - anglais - NLM (National Library of Medicine)

bayshore pharmaceuticals llc - sotalol hydrochloride (unii: hec37c70xx) (sotalol - unii:a6d97u294i) - sotalol af are indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm. because sotalol af can cause life-threatening ventricular arrhythmias, it should be reserved for patients in whom afib/afl is highly symptomatic. patients with paroxysmal afib whose afib/afl that is easily reversed (by valsalva maneuver, for example) should usually not be given sotalol af (see warnings ). in general, antiarrhythmic therapy for afib/afl aims to prolong the time in normal sinus rhythm. recurrence is expected in some patients (see clinical studies ). sotalol is also indicated for the treatment of documented life-threatening ventricular arrhythmias and is marketed under the brand name betapace® (sotalol hydrochloride) . sotalol hydrochloride tablets, however, must not be substituted for sotalol hydrochloride tablets (af) because of significant differences in labeling (i.e., patient package insert, dosing administration and safety information). sotalol af is contraindicated in patients with sinus bradycardia (<50 bpm during waking hours), sick sinus syndrome or second and third degree av block (unless a functioning pacemaker is present), congenital or acquired long qt syndromes, baseline qt interval >450 msec, cardiogenic shock, uncontrolled heart failure, hypokalemia (<4 meq/l), creatinine clearance <40 ml/min, bronchial asthma and previous evidence of hypersensitivity to sotalol. the safety and effectiveness of sotalol af in children have not been established. however, the class iii electrophysiologic and beta-blocking effects, the pharmacokinetics, and the relationship between the effects (qtc interval and resting heart rate) and drug concentrations have been evaluated in children aged between 3 days and 12 years old. (see clinical pharmacology .)

États-Unis - anglais - NLM (National Library of Medicine)

oxford pharmaceuticals, llc - sotalol hydrochloride (unii: hec37c70xx) (sotalol - unii:a6d97u294i) - sotalol hydrochloride tablets are indicated for the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia (vt). limitation of use sotalol hydrochloride tablets have not been shown to enhance survival in patients with life-threatening ventricular arrhythmias. sotalol hydrochloride tablets are indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of afib/afl) in patients with highly symptomatic afib/afl who are currently in sinus rhythm. limitation of use: because sotalol hydrochloride tablets can cause life-threatening ventricular arrhythmias, reserve its use for patients in whom afib/afl is highly symptomatic. patients with paroxysmal afib that is easily reversed (by valsalva maneuver, for example) should usually not be given sotalol hydrochloride tablets. sotalol hydrochloride tablets are contraindicated in patients with: - sinus bradycardia, sick sinus syndrome, second and third degree av block, unless a functioning pac

États-Unis - anglais - NLM (National Library of Medicine)

marlex pharmaceuticals inc - sotalol hydrochloride (unii: hec37c70xx) (sotalol - unii:a6d97u294i) - sotalol af are indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm. because sotalol af can cause life-threatening ventricular arrhythmias, it should be reserved for patients in whom afib/afl is highly symptomatic. patients with paroxysmal afib whose afib/afl that is easily reversed (by valsalva maneuver, for example) should usually not be given sotalol af (see warnings ). in general, antiarrhythmic therapy for afib/afl aims to prolong the time in normal sinus rhythm. recurrence is expected in some patients (see clinical studies ). sotalol is also indicated for the treatment of documented life-threatening ventricular arrhythmias and is marketed under the brand name betapace® (sotalol hydrochloride) . sotalol hydrochloride tablets, however, must not be substituted for sotalol hydrochloride tablets (af) because of significan

États-Unis - anglais - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - sotalol hydrochloride (unii: hec37c70xx) (sotalol - unii:a6d97u294i) - sotalol is indicated for the treatment of life-threatening, documented ventricular arrhythmias, such as sustained ventricular tachycardia (vt). limitation of use: sotalol may not enhance survival in patients with ventricular arrhythmias. because of the proarrhythmic effects of sotalol, including a 1.5 to 2% rate of torsade de pointes (tdp) or new ventricular tachycardia/fibrillation (vt/vf) in patients with either non-sustained ventricular tachycardia (nsvt) or supraventricular arrhythmias (svt), its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. avoid treatment of patients with asymptomatic ventricular premature contractions [see warnings and precautions ( 5.2).] sotalol is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of afib/afl) in patients with symptomatic afib/afl who are currently in sinus rhythm. limitation of use: because sotalol can cause life-threatening ventricular arrhythmias, reserve its use fo

États-Unis - anglais - NLM (National Library of Medicine)

aurobindo pharma limited - sotalol hydrochloride (unii: hec37c70xx) (sotalol - unii:a6d97u294i) - sotalol hydrochloride tablets (af) are indicated for the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia (vt). limitation of use:   sotalol hydrochloride tablets (af) has not been shown to enhance survival in patients with life-threatening ventricular arrhythmias. sotalol hydrochloride tablets (af) are indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of afib/afl) in patients with highly symptomatic afib/afl who are currently in sinus rhythm.  limitation of use: because sotalol hydrochloride tablets (af) can cause life-threatening ventricular arrhythmias, reserve its use for patients in whom afib/afl is highly symptomatic. patients with paroxysmal afib that is easily reversed (by valsalva maneuver, for example) should usually not be given sotalol hydrochloride tablets af. sotalol hydrochloride tablets (af) are contraindicated in patients with: - sinus bradycardia, sick sinus syndrome, second and third degree av block,